Therapeutic potential of targeting the complement cascade in critical care medicine

Critical Care Medicine

Volumn 31, Issue 1 SUPPL., 2003, Pages

  Bhole, Deepak ^a   Stahl, Gregory L ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

C1q; C3; C3a; C5a; Cardiopulmonary bypass; Inflammation; Mannose binding protein; Pexelizumab; Sepsis; TP 10

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; MANNOSE BINDING PROTEIN; PEXELIZUMAB; UNCLASSIFIED DRUG;

CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HEART INFARCTION; HUMAN; INFLAMMATION; INTENSIVE CARE; ISCHEMIA; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS; SHOCK;

EID: 0037248345     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200301001-00014     Document Type: Review

References (83)

1. Stahl GL: Reperfusion-injury during surgery: Role of the endothelium, oxidative stress and complement activation. New Surg 2001; 1:62-66
2. Shernan SK, Collard CD: Role of the complement system in ischaemic heart disease. BioDrugs 2001; 15:595-607
3. Turner MW: Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998; 199:327-339
4. Thiel S, Vorup-Jensen T, Stover CM, et al: A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997; 386:506-510
5. Ji X, Azumi K, Sasaki M, et al: Ancient origin of the complement lectin pathway revealed by molecular cloning of mannan binding: Protein-associated serine protease from a urochordate, the Japanese ascidian, Halocynthia roretzi. Proc Natl Acad Sci U S A 1997; 94:6340-6345
6. Matsushita M, Endo Y, Fujita T: Cutting edge: Complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol 2000; 164:2281-2284
7. Law SKA, Reid KBM. Complement. New York, IRL Press, 1995
8. Jagels MA, Daffern PJ, Hugli TE: C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: Epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology 2000; 46:209-222
9. DiScipio RG, Daffern PJ, Jagels MA, et al: A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 1999; 162:1127-1136
10. Tonnesen MG, Anderson DC, Springer TA, et al: Adherence of neutrophils to cultured human microvascular endothelial cells. Stimulation by chemotactic peptides and lipid mediators and dependence upon the Mac-1, LFA-1, p150,95 glycoprotein family. J Clin Invest 1989; 83:637-646
11. Sacks T, Moldow CF, Craddock PR, et al: Oxygen radicals mediate endothelial cell damage by complement- stimulated granulocytes: An in vitro model of immune vascular damage. J Clin Invest 1978; 61:1161-1167
12. Saadi S, Holzknecht RA, Patte CP, et al: Endothelial cell activation by pore-forming structures: Pivotal role for interleukin-1alpha. Circulation 2000; 101:1867-1873
13. Kilgore KS, Flory CM, Miller BF, et al: The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996; 149:953-961
14. Marks RM, Todd RFI, Ward PA: Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature 1989; 339:314-317
15. Wada K, Montalto MC, Stahl GL: Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology 2001; 120:126-133
16. Zhou W, Farrar CA, Abe K, et al: Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105:1363-1371
17. Vakeva A, Agah A, Rollins SA, et al: Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97:2259-2267
18. Zhao H, Montalto MC, Pfeiffer KJ, et al: Murine model of gastrointestinal ischemia associated with complement dependent injury. J Appl Physiol 2002; 93:338-345
19. Kilgore KS, Schmid E, Shanley TP, et al: Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappaB activation. Am J Pathol 1997; 150:2019-2031
20. Tedesco F, Pausa M, Nardon E, et al: The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185:1619-1627
21. Collard CD, Agah A, Reenstra WR, et al: Endothelial nuclear factor-kB translocation and vascular cell adhesion molecule-1 induction by complement: Inhibition with anti-human C5 therapy or cGMP analogues. Arterioscler Thromb Vasc Biol 1999; 19:2623-2629
22. Kilgore KS, Shen JP, Miller BF, et al: Enhancement by the complement membrane attack complex of tumor necrosis factor-α-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995; 155:1434-1441
23. Foreman KE, Vaporciyan AA, Bonish BK, et al: C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94:1147-1155
24. Stahl GL, Reenstra WR, Frendl G: Complement mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of the terminal membrane attack complex. Circ Res 1995; 76:575-583
25. From the Centers for Disease Control. Increase in National Hospital Discharge Survey rates for septicemia - United States, 1979-1987. JAMA 1990; 263:937-938
26. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
27. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214
28. Danner RL, Elin RJ, Hosseini JM, et al: Endotoxemia in human septic shock. Chest 1991; 99:169-175
29. Luderitz O, Tanamoto K, Galanos C, et al: Lipopolysaccharides: Structural principles and biologic activities. Rev Infect Dis 1984; 6:428-431
30. Kengatharan KM, De Kimpe S, Robson C, et al: Mechanism of Gram-positive shock: Identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med 1998; 188:305-315
31. Smedegard G, Cui L, Hugli TE: Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol 1989; 135:489-497
32. Bengtson A, Lannsjo W, Heideman M: Complement and anaphylatoxin responses to cross-clamping of the aorta. Br J Anaesth 1987; 59:1093-1097
33. Heideman M, Norder-Hansson B, Bengtson A, et al: Terminal complement complexes and anaphylatoxins in septic and ischemic patients. Arch Surg 1988; 123:188-192
34. Cinco M, Perticarari S, Presani G, et al: Biological activity of a peptidoglycan extracted from Leptospira interrogans: In vitro studies. J Gen Microbiol 1993; 139:2959-2964
35. Kirschfink M, Blase L, Engelmann S, et al: Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J Immunol 1997; 158:1324-1331
36. Wessels MR, Butko P, Ma M, et al: Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A 1995; 92:11490-11494
37. Alper CA, Abramson N, Johnston RB Jr, et al: Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med 1970; 282:350-354
38. Kildsgaard J, Hollmann TJ, Matthews KW, et al: Cutting edge: Targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol 2000; 165:5406-5409
39. Boes M, Prodeus AP, Schmidt T, et al: A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 1998; 188:2381-2386
40. Celik I, Stover C, Botto M, et al: Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis. Infect Immun 2001; 69:7304-7309
41. White P, Liebhaber SA, Cooke NE: 129X1/SvJ mouse strain has a novel defect in inflammatory cell recruitment. J Immunol 2002; 168:869-874
42. Super M, Thiel S, Lu J, et al: Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989; 2:1236-1239
43. Garred P, Madsen HO, Hofmann B, et al: Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 1995; 346:941-943
44. Takahashi K, Gordon J, Hong L, et al: Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis. Microbes Infect 2002, In Press
45. Mohr M, Höpken U, Oppermann M, et al: Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur J Clin Invest 1998; 28:227-234
46. Stevens JH, O'Hanley P, Shapiro JM, et al: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986; 77:1812-1816
47. Czermak BJ, Sarma V, Pierson CL, et al: Protective effects of C5a blockade in sepsis. Nat Med 1999; 5:788-792
48. Huber-Lang M, Sarma VJ, Lu KT, et al: Role of C5a in multiorgan failure during sepsis. J Immunol 2001; 166:1193-1199
49. Papathanassoglou ED, Moynihan JA, Ackerman MH: Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework. Crit Care Med 2000; 28:537-549
50. Mahidhara R, Billiar TR: Apoptosis in sepsis. Crit Care Med 2000; 28:N105-N113
51. Guo RF, Huber-Lang M, Wang X, et al: Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000; 106:1271-1280
52. Riedemann NC, Guo RF, Laudes IJ, et al: C5a receptor and thymocyte apoptosis in sepsis. FASEB J 2002; 16:887-888
53. Riedemann NC, Guo RF, Neff TA, et al: Increased C5a receptor expression in sepsis. J Clin Invest 2002; 110:101-108
54. Strachan M, Woodruff TM, Haaima G, et al: A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol 2000; 164:6560-6565
55. Larrick JW, Wang J, Fendly BM, et al: Characterization of murine monoclonal antibodies that recognize neutralizing epitopes on human C5a. Infect Immun 1987; 55:1867-1872
56. Olson LM, Moss GS, Baukus O, et al: The role of C5 in septic lung injury. Ann Surg 1985; 202:771-776
57. Sun Z, Wang X, Deng X, et al: Phagocytic and intestinal endothelial and epithelial barrier function during the early stage of small intestinal ischemia and reperfusion injury. Shock 2000; 13:209-216
58. Mangano DT: Cardiovascular morbidity and CABG surgery - A perspective: Epidemiology, costs, and potential therapeutic solutions. J Card Surg 1995; 10:366-368
59. Van Oeveren W, Kazatchkine MD, Descamps-Latscha B, et al: Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985; 89:888-899
60. Kirklin JK, Westaby S, Blackstone EH, et al: Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86:845-857
61. Gu YJ, Mariani MA, Boonstra PW, et al: Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass - The role of tissue injury by surgical incision. Chest 1999; 116:892-898
62. Mollnes TE. Biocompatibility: Complement as mediator of tissue damage and as indicator of incompatibility. Exp Clin Immunogent 1997; 14:24-29
63. Chenoweth DE, Cooper SW, Hugli TE, et al: Complement activation during cardiopulmonary bypass. Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981; 304:497-503
64. Cheung AK, LeWinter M, Chenoweth DE: Cardiopulmonary effects of cuprophane-activated plasma in the swine. Kidney Int 1986; 29:799-806
65. Rent R, Ertel N, Eisenstein R, et al: Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J Immunol 1975; 114:120-124
66. Weiler JM, Edens RE, Linhardt RJ, et al: Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992; 148:3210-3215
67. Pekna M, Borowiec J, Fagerhol MK, et al: Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1994; 28:5-11
68. Pekna M, Hagman L, Haldén E, et al: Complement activation during cardiopulmonary bypass: Effects of immobilized heparin. Ann Thorac Surg 1994; 58:421-424
69. Hsu LC: Heparin-coated cardiopulmonary bypass circuits: Current status. Perfusion 2001; 16:417-428
70. Weisman HF, Bartow T, Leppo MK, et al: Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249:146-151
71. Rioux P: TP-10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs 2001; 2:364-371
72. Lazar HL, Bao Y, Gaudiani J, et al: Total complement inhibition: An effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Circulation 1999; 100:1438-1442
73. Chai PJ, Nassar R, Oakeley AE, et al: Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 2000; 101:541-546
74. Rinder CS, Rinder HM, Smith BR, et al: Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96:1564-1572
75. Fitch JCK, Rollins SA, Matis LA, et al: Pharmacology and biological effcacy of a recombinant, humanized, single chain antibody, C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery utilizing cardiopulmonary bypass. Circulation 1999; 100:2499-2509
76. Mollnes TE, Song WC, Lambris JD: Complement in inflammatory tissue damage and disease. Trends Immunol 2002; 23:61-64
77. Roos A, Nauta M, Broers D, et al: Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol 2001; 167:7052-7059
78. Zhao H, Wakamiya N, Suzuki Y, et al: Identification of human mannose binding lectin (MBL) recognition sites for novel inhibitory antibodies. Hybrid Hybridomics 2002; 21:25-36
79. Collard CD, Vakeva A, Morrissey MA, et al: Complement activation following oxidative stress: Role of the lectin complement pathway. Am J Pathol 2000; 156:1549-1556
80. Kirschfink M, Mollnes TE: C1-inhibitor: An anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2001; 2:1073-1083
81. Jiang HX, Wagner E, Zhang HM, et al: Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001; 194:1609-1616
82. Fung M, Loubser PG, Undar A, et al: Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg 2001; 122:113-122
83. Morikis D, Assa-Munt N, Sahu A, et al: Solution structure of Compstatin, a potent complement inhibitor. Protein Sci 1998; 7:619-627